A comprehensive expression profile of tRNA-derived fragments in papillary thyroid cancer

Shiting Shan1,2 | Yuting Wang2,3 | Chunfu Zhu2

1Nanjing Medical University, Nanjing, China
2Department of General Surgery, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, China
3Dalian Medical University, Dalian, China

Correspondence
Chunfu Zhu, Department of General Surgery, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou 213000, China. Email: zcfmlm@njmu.edu.cn

Funding information
Social Development Foundation of Science and Technology of Jiangsu (BE2016658), the Changzhou Sci & Tech Program (CE20165020), the High-Level Medical Talents Training Project of Changzhou (2016CZLU007), and the Project of Changzhou medical innovation team (CCX201807).

Abstract
Background: The incidence of thyroid cancer has been on a rise. Papillary thyroid cancer (PTC) is the most common type of malignant thyroid tumor and accounts for approximately 85% of thyroid cancer cases. Although the genetic background of PTC has been studied extensively, relatively little is known about the role of small noncoding RNAs (snRNAs) in PTC. tRNA-derived fragments (tRFs) represent a newly discovered class of snRNAs that exist in many species and play key roles in various biological processes.

Methods: In this study, we used high-throughput next-generation sequencing technology to analyze the expression of tRFs in samples from PTC tissues and normal tissues. We selected four tRFs to perform qPCR to determine the expression levels of these molecules and make bioinformatic predictions.

Results: We identified 53 unique tRFs and transfer RNA halves (tsRNAs). The 10 most upregulated tRFs and tsRNAs were tRF-39-I6D38B7S1RMH5M2, tRF-21-E48B3RB, tRF-18-JMRPFQDY, tRF-17-202L2YF, tRF-17-VBY9PYJ, tRF-18-YRRHQFD2, tRF-21-WE884U1DD, tRF-41-EXZ109BZBZO54YB, tRF-39-HPDEXK7S1RN9M2I, and tRF-20-15S2P46I. The 10 most downregulated tRFs and tsRNAs were tRF-31-HQ9M739P8WQ0B, tRF-43-5YXENDBP1UUK7VZV, tRF-38-RZQHQ9M739P8WD8, tRF-25-9M739P8WQ0, tRF-33-V6Z3M8ZLSSXU6, tRF-27-MY73H3RXPLM, tRF-26-DBNIB9I1KQ0, tRF-38-Z9HM8W47W1R7HX, tRF-40-Z6V6Z3M8ZLSSXUOL, and tRF-39-YQHQ9M739P8WQ0EB. qPCR verification of cell lines and tissue samples yielded results consistent with the sequencing analysis. As tRF-39 expression showed the maximum difference between PTC cells and normal cells, we chose this tRF to predict targets and perform functional tRF and tsRNA enrichment analysis.

Conclusion: In this study, we provided a comprehensive catalog of tRFs involved in PTC and assessed the abnormal expression of these fragments. Through qPCR verification, tRF-39-0VL8K87S1RMHMM12E2 was found to be the most significantly upregulated tRF. Further tRF and enrichment analysis revealed that tRF-39 was mostly enriched in the "metabolic pathways." These preliminary findings can be used as the basis for further research studies based on the functional role of tRFs in patients with PTC.

KEYWORDS
expression profile, papillary thyroid cancer, tRNA-derived fragments

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, LLC.
**INTRODUCTION**

Thyroid cancer is one of the most common malignant tumors in the endocrine system and has registered an annual growth rate of 2% in recent decades. Papillary thyroid cancer (PTC) is the most common type of malignant thyroid tumor, with more than 10 known subtypes that account for 85-90% of all thyroid malignancies. Fortunately, most PTCs are relatively inert and the 10-year survival rate for patients undergoing a glandectomy or total thyroidectomy plus I\textsubscript{131} treatment is greater than 95%. However, in approximately 10% of patients with PTC, recurrence or metastasis occurs and requires further intervention. Formulating treatments for PTC requires a thorough understanding of the molecular mechanisms underlying the pathogenesis and progression of the disease. Although the genetic background of PTC has been extensively studied, relatively little is known regarding the role of small non-coding RNAs (sncRNAs) other than microRNA (miRNA). An earlier study led to the discovery of a new class of sncRNA derived from tRNA, known as tRNA-derived fragments (tRFs). tRFs have functions similar to those of miRNA, with the ability to directly bind to mRNA, inhibit protein translation, and cleave partially complementary targets. tRFs can also regulate gene expression via competitive binding with proteins of Ago (Argonaute) family, thereby affecting the silencing efficiency of target genes. In addition, tRFs and their analogs can affect the tumor gene mRNA binding protein Y-box binding protein 1 (YBX1), by blocking its interaction with oncogenic mRNA and destabilizing oncogene mRNAs, thereby inhibiting tumor cell infiltration. tRFs can also regulate protein biosynthesis by affecting the translation. Furthermore, research studies have shown that tRFs can be used as guide RNAs in viral reverse transcription (RT) and can combine with primer RNA to initiate RT. When combined with cytochrome C, tRFs inhibit the formation of apoptotic bodies. Finally, studies have shown that tRFs exist in hematopoietic cells, lymphocytes, and the blood circulation system, suggesting that these fragments may play important role in the immune response.

Previous studies have shown that tRFs play regulatory roles in various human diseases such as cancers, pathological stress injuries, metabolic diseases, viral infections, and diseases of nervous system. However, the understanding of how tRFs regulate cancer progression remains unknown. Previous studies have indicated that tRFs and transfer RNA (tRNA) halves are involved in cancers of breast, prostate, colorectum, liver, and pancreatic, although the potential role of tRFs and tRNA halves in thyroid cancer is yet to be elucidated. In this study, we sought to explore how the expression and function of tRFs regulate cancer cells in patients with PTC.

**MATERIAL AND METHODS**

**2.1 Sample collection**

Four patients (one woman, three men; age range, 30-50 years), all of whom had undergone surgery for PTC at the Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University (Jiangsu, China), were recruited in 2019 to participate in this study (Table 1). All patients had no underlying disease and no history of previous surgical procedures. After the operation, they received hormone replacement therapy. Each patient provided written informed consent, and the ethics committee of Changzhou Second People’s Hospital affiliated to Nanjing Medical University approved the study protocol. The specific stage of PTC in each patient was determined based on the thyroid cancer TNM staging system published by the American Joint Committee on Cancer in 2017. In total, four pairs of PTC specimens and adjacent control tissues (with a distance of 2 cm)

| Patient number | Age (years) | Sex | Tumor size (cm) | Tumor stage | Pathological description of tumor |
|----------------|-------------|-----|----------------|-------------|---------------------------------|
| 1              | 45          | Male| 0.6            | T1N0M0      | Mini papillary carcinoma, no lymph node metastasis |
| 2              | 37          | Male| 1.2            | T1N1M0      | Papillary carcinoma, left central lymph node 1/1 metastasis |
| 3              | 48          | Male| 2.5            | T2N0M0      | Papillary carcinoma, no lymph node metastasis, tumor invasion of left recurrent laryngeal nerve |
| 4              | 67          | Female| 0.9        | T1N1M0      | Papillary carcinoma, 1/4 lymph node metastasis in the central area, 1/1 lymph node metastasis in the left 2A area, and 6/19 lymph node metastasis in the left 4 area |

**TABLE 1** Patient and tumor characteristics

Abbreviations: M, metastasis; N, node; T, tumor.
from the tumor) were collected for tRF sequencing and immediately stored in liquid nitrogen.

**2.2 | Types of tRNA-derived small RNA (tsRNA)**

Small RNAs derived from tRNA (tsRNAs) refer to the nuclease, such as Dicer or Angiopoietin (ANG), specific to tRNAs in certain cells or tissues, or under certain conditions such as stress or hypoxia. tsRNA is a type of sncRNA, which are widely expressed in prokaryotic and eukaryotic transcriptomes and is produced by cleavage of mature or precursor tRNA at different sites. There are two main types of tsRNAs, tRFs, and tRNA halves. tsRNAs are divided into the following five categories based on their biogenesis and relative length: 1) 5′-half: A 5′-tRNA half-molecule that is produced by ANG specifically cleaving at the anticodon loop of mature tRNA under various stress conditions; 2) 3′-half: A 3′-tRNA half-molecule that is produced by ANG specifically cleaving at the anticodon loop of mature tRNA under various stress conditions; 3) 5′-tRF: A fragment from mature tRNA in which the 5′ end is cleaved at the D-loop or anticodon stem; 4) i-tRF: a fragment originating from the inside of mature tRNA and according to whether the 5′ sequence or the 3′ sequence contains anticodon cleavage sites, tsRNAs are divided into two subtypes, namely 5′ and 3′, with a length of 31-40 nt. 5′ start at the 5′ end of the mature tRNA and end at the anticodon loop, whereas 3′ includes the anticodon loop and the 3′ end. The same type of tsRNA can be cut from multiple tRNAs, however, the function of such tsRNA derived from different tRNA sources will produce several types of tRF with different biological functions. tRF can reduce the overall translation speed by 10% to 15%; part of the 5′ end from tRNAAla and tRNACys can be assembled into a G4 motif that can competitively bind eIF4G/eIF4A in the translation initiation complex, thereby tRF inhibit Cap-dependent mRNA translation. The known tRNA and tsRNA ratio distributions are shown in Figures 1 and 2, respectively. As a sncRNA, the length of mature tsRNA generated by tRNA shearing generally ranges from 16 to 35 nt (Figure 3).
2.3  tRF sequencing

As tRFs are short fragments, the library was constructed using the following protocol: the total RNA or purified tsRNA fragments were extracted from samples with the 3′ end and the 5′ connector joined successively. Then, complementary DNA (cDNA) was synthesized using RT, followed by PCR expansion. The target fragment library was recovered via gel extraction and sequenced on
the computer. Illumina HiSeq 2500 was used to sequence the raw data reads. The joints at both ends of the reads were removed and low-quality reads and reads with a fragment length < 15 nt were also removed to complete the initial data filtering and to obtain high-quality data (clean reads). Clean reads were compared with the reference genome to obtain a genome-wide read distribution map, and were annotated according to snRNA classification. The expressions of identified tsRNAs and cluster tsRNAs were calculated, and tsRNAs were analyzed for differential expression between samples.

2.4 | Quantitative RT-PCR (qRT-PCR)

We selected four tRFs for PCR verification. The sequences of the four tRFs are shown in Table 2. First, we extracted total RNA from PTC cell lines, PTC tissue, normal thyroid cell lines, and normal tissue using RL lysate. The RNA was reverse-transcribed at 42°C for 60 min followed by at 70°C for 10 min, using the Bulge-Loop miRNA qRT-PCR Starter Kit (Guangzhou Ribobio Biological Technology, China). Next, qPCR was performed using U6 small nuclear RNA (snRNA) as an internal control. After adding the cDNA and forward and reverse primers designed specifically for each tRF by Ribobio, the fragments were incubated at 95°C for 10 min, followed by 60 cycles of amplification at 95°C for 2 s, 60°C for 20 s, and 70°C for 10 s on the Roche LightCycler 480 Real-Time PCR System (Roche LightCycler 480 system, Basel, Switzerland). Finally, the relative expression levels of each specific tRF in each sample group were normalized using the 2^-ΔΔCt method.

2.5 | Predicted targets of tRF and tsRNA

tsRNA target gene prediction mainly considers the complementary pairing of tsRNA and mRNA 3’ untranslated regions. Different software programs predict different target genes based on the complementary pairing of tsRNA and its target site. Therefore, we used a combination of the following three unique software programs to predict targets: MiRanda (http://www.microrna.org/microrna/home.do), RNAhybrid (http://www.bibiservcebiclefel.de/rnahybrid/), and targetScan (http://www.targetscan.org/). We then screened and sorted the results from the three programs and used the prediction results as the candidate target genes of tsRNA.

| Table 2 | tRFs and tRNAs selected for validation via quantitative PCR |
|---------|-----------------------------------------------------------|
| tsRNA_ID | Sequence |
| tRF-27-PIR8YP9LON3 | GCACCTGGTTGTCATGGTTAATTCT |
| tRF-34-YSV4V47Q2WW1J1 | TTCCGTAGTGTAGTGGTTATCACGTTCGCCTCAC |
| tRF-38-0VL8K87SIRMM12V | ACCGCCCGCGGCGGGTTCCGATTTCCCGCGTCAGGGGAACC |
| tRF-39-0VL8K87SIRMM12E2 | ACCGCCCGCPCCGGGTTCCGATTTCCCGCGTCAGGGGAACC |

Abbreviations: tRF, transfer RNA-derived fragment; tsRNA, tRNA-derived small RNA.

2.6 | Functional tRF and tsRNA enrichment analysis

Biological pathway analysis was performed in conjunction with the Kyoto encyclopedia of genes and genomes (KEGG) Biological Pathway Database (https://www.kegg.jp/). We placed the candidate target genes into the biological pathway for comprehensive analysis and analyzed the degree of influence and regularity of the functional variation on the biological pathway. The gene function enrichment analysis process was thus, divided into two steps, a KEGG biological pathway annotation, and an enrichment analysis. For this analysis, p values were calculated using Fisher’s exact test, with a p value of 0.05 used as the significance threshold. Significant signal transduction and disease pathways were identified, thereby providing distribution information and significance status for gene sets in the KEGG category. Gene ontology analysis was used to perform functional annotation for each gene and calculate the most significant function in a specific series of genes via statistical analysis, for example, by using hypergeometric distribution.

3 | RESULTS

3.1 | tRF sequencing

We detected thousands of differentially expressed tRFs in PTC through high-throughput next-generation sequencing technology. Here, we present 53 differentially expressed tRFs (Table 3), including 19 downregulated tRFs and tsRNAs, and 34 upregulated tRF and tsRNAs, which exhibited abundant expression and were significantly different between the thyroid cancer samples and normal tissue samples. These 53 tRFs were derived from different types of tRNAs and belonged to different tRF types. A heat map representing the expression in various samples is shown in Figure 4.

3.2 | Quantitative RT-PCR (qRT-PCR)

For further qPCR verification, we chose four tRFs (tRF-38-0VL8K87SIRMM12V, tRF-39-0VL8K87SIRMM12E2, tRF-27-PIR8YP9LON3, and tRF-34-YSV4V47Q2WW1J1), which were expressed abundantly and were significantly different between the thyroid cancer samples and normal tissue samples. qPCR analysis demonstrated that tRF-38-0VL8K87SIRMM12V and tRF-39-0VL8K87SIRMM12E2 were upregulated whereas tRF-34-YSV4V47Q2WW1J1 and...
| tsRNA_ID           | tRNA     | tsRNA type | Fold change, T/N | p value   |
|--------------------|----------|------------|------------------|-----------|
| **Upregulated tsRNA** |          |            |                  |           |
| tRF-39-i6D388751RMH5M12 | ArgTCT   | 3′-tRF     | 3.9069           | 0.014928  |
| tRF-21-2E489B3RB    | MetCAT   | 3′-half    | 3.8826           | 0.021853  |
| tRF-18-JMRPFQDY     | LysCTT   | i-tRF      | 3.6147           | 0.014696  |
| tRF-17-202L2YF      | PheGAA   | i-tRF      | 3.5546           | 0.037522  |
| tRF-17-VBY9PYJ      | GlyGCC   | i-tRF      | 3.5025           | 0.022305  |
| tRF-18-YRRHQFD2     | GlyCCC   | 3′-tRF     | 3.4594           | 0.037242  |
| tRF-21-WE884U1DD    | TyrGTA   | 3′-tRF     | 3.4594           | 0.039407  |
| tRF-41-EX2ZI09B2BZOS4YB | ValTAC | i-tRF      | 3.4263           | 0.041616  |
| tRF-39-HPDEXK7S1RN59M12 | ArgCCG | 3′-tRF     | 3.1699           | 0.042129  |
| tRF-20-1S52P46l     | MetCAT   | 3′-half    | 2.8836           | 0.012036  |
| tRF-17-9N1EWM       | GluCTC   | i-tRF      | 2.3410           | 0.016507  |
| tRF-37-7O58J0K8UMPLBIO | LeuTAA | 5′-half    | 2.3172           | 0.018091  |
| tRF-31-F9LKXNYQUIVB | CysGCA   | 5′-tRF     | 2.2257           | 0.033673  |
| tRF-42-7O58J0K8UMPLBIOB3 | LeuTAA | 5′-tRF     | 2.1699           | 0.039598  |
| tRF-17-K5KKOV2      | AsnGTT   | 3′-tRF     | 2.0875           | 0.015291  |
| tRF-18-69M8L004     | ArgTCT   | 5′-tRF     | 2.0395           | 0.047687  |
| tRF-37-BR9M3W085Q25V2 | ArgTCT | 3′-tRF     | 1.5567           | 0.047326  |
| tRF-38-0VL8K875IRMM12V | GluTTC | 3′-tRF     | 2.3693           | 0.039325  |
| tRF-39-0VL8K875IRMM12E2 | GluTTC | 3′-tRF     | 3.2978           | 0.040484  |
| **Downregulated tsRNA** |          |            |                  |           |
| tRF-31-HQ9M739P8WQ0B | GluTTC   | i-tRF      | -2.0213          | 0.040330  |
| tRF-43-5YXENDBP1IUUK7VZV | HisGtG | i-tRF      | -2.2395          | 0.040484  |
| tRF-38-RZYQHQ9M739P8WD8 | GluTTC | i-tRF      | -2.6230          | 0.033734  |
| tRF-25-M739P8WQ0    | GluTTC   | i-tRF      | -2.3933          | 0.030280  |
| tRF-33-V6Z3M8ZLS5XUD6 | GluTTC | i-tRF      | -2.4111          | 0.029211  |
| tRF-27-MY73H3RXPLM  | GlyTCC   | i-tRF      | -2.4374          | 0.044427  |
| tRF-26-DBNIB911KQ0  | SerGCT   | i-tRF      | -2.4703          | 0.045635  |
| tRF-38-Z9HM1BW47W1R7HX | GluTTC | i-tRF      | -2.6933          | 0.022304  |
| tRF-40-Z6V6Z3M8ZLS5XUOL | GluTTC | i-tRF      | -2.8908          | 0.019767  |
| tRF-39-0VL8K875IRMM12V | GluTTC | i-tRF      | -3.0422          | 0.032495  |
| tRF-29-JNS5VF3R3ZVFDD | AlaTGc | i-tRF      | -3.1699          | 0.041342  |
| tRF-33-BR9N9S343L2DB | GluTTC   | i-tRF      | -3.1802          | 0.039608  |
| tRF-34-YSV4V47Q2WW1J1 | ValCac | i-tRF      | -3.2677          | 0.032495  |
| tRF-37-Z6V6Z3M8ZLS5XUL | GluTTC | i-tRF      | -3.3563          | 0.010854  |
| tRF-26-OIQQ4QPQRWD  | SerGCT   | i-tRF      | -3.3563          | 0.010854  |
| tRF-27-PMT8Y9P9LON3  | ValCac   | 5′-tRF     | -3.3563          | 0.010854  |
| tRF-31-U2O1B542UPX1B | LysTTT   | 3′-tRF     | -3.3923          | 0.032766  |
| tRF-31-00BY484KRIME  | SerGCT   | i-tRF      | -3.4594          | 0.032259  |
| tRF-24-B0845J862E    | SerTGA   | i-tRF      | -3.5546          | 0.043139  |
| tRF-27-08F4BDNZBO4   | ThrTGT   | i-tRF      | -3.6147          | 0.044530  |
| tRF-33-YQHQ9M739P8WD8 | GluTTC   | i-tRF      | -3.6358          | 0.020345  |
| tRF-38-YQHQ9M739P8WQ07 | GluTTC | i-tRF      | -3.6894          | 0.007831  |
| tRF-36-YQHQ9M739P8WQ0B | GluTTC | i-tRF      | -3.7654          | 0.018644  |
| tRF-42-RZYQHQ9M739P8WQ0F | GluTTC | i-tRF      | -3.8074          | 0.025013  |
Table 3 (Continued)

| tsRNA_ID       | tsRNA type | Fold change, T/N | p value |
|----------------|------------|------------------|---------|
| tRF-37-BF82Z4D7OOJ0QXX | HisGTG     | i-tRF            | −3.8074 | 0.034026 |
| tRF-42-IWOMXF026ZEDKZIXJ | HisGTG     | i-tRF            | −3.8244 | 0.042981 |
| tRF-35-YQHQ9M79P9BWQ0 | GluTTC     | i-tRF            | −4.0356 | 0.010854 |
| tRF-36-Z6V6Z3M8ZLSSXU0 | GluTTC     | i-tRF            | −4.0589 | 0.046194 |
| tRF-39-ZZJQY5SRVY1ZMMVX | GluTTC     | i-tRF            | −4.1015 | 0.004510 |
| tRF-34-YQHQ9M79P9WIL | GluTTC     | i-tRF            | −4.1224 | 0.006380 |
| tRF-37-U5YKFN8YDZDL9P | ValTAC     | i-tRF            | −4.1293 | 0.032399 |
| tRF-30-BY4DB84KRIMUF | SerGCT     | i-tRF            | −4.2854 | 0.009510 |
| tRF-39-Z6V6Z3M8ZLSSXUH7 | GluTTC     | i-tRF            | −4.4594 | 0.039325 |
| tRF-37-YQHQ9M79P9WQOF | GluTTC     | i-tRF            | −5.4595 | 0.011287 |

Abbreviations: i-tRF, tRNA half; T/N, tumor/normal tissue; tiRNA, transfer RNA half; tRF, transfer RNA-derived fragment; tsRNA, tRNA-derived small RNA.

Figure 5  The expression of tRF-39. tRF-39 was upregulated in PTC cell lines and tissue samples. (A) tRF-39 was upregulated in PTC cells, **p < 0.01; (B) tRF-39 was upregulated in PTC tissue samples, ****p < 0.0001. The data are expressed as mean ± SD

Figure 6 Target Gene Prediction Venn Diagram. The intersection of the target genes of tsRNA shown in the Venn diagram (venn/Venn diagram) in the three softwares have 553 target genes by miRanda, RNHybrid, and TargetScan. KEGG analysis was also performed on the target genes and an example of the KEGG channel analysis results is shown in Figure 7. tRF-39-0VL8K-87SIRM12E2 was mostly enriched in the “metabolic pathways” section of the figure. Lastly, a candidate target gene KEGG pathway bubble chart showing the proportion of enriched differential genes in the background genes of the pathway is presented in Figure 8.

4 | DISCUSSION

As sequencing technology has improved, research into sncRNAs has progressed and led to the discovery of tRFs. Since the initial tRF-27-PIR8YP9LON3 were downregulated in the thyroid cancer cell lines. Also, we perform qPCR in 10 pair tissue samples whom had undergone surgery for PTC at the Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University. As a result, tRF-38-0VL8K87SIRM12V and tRF-39-0VL8K87SIRM12E2 were upregulated and tRF-34-Y5V4Y47Q2WW1J1 and tRF-27-PIR8Y-P9LON3 were downregulated in PTC tissues sample, which was consistent with the cell line analysis. tRF-39 expression showed the maximum difference in PTC cell lines and PTC tissue samples. The results of qPCR are shown in Figure 5.

3.3 | Predicted targets of functional tRF and enrichment analysis

The target genes of tsRNAs that were produced from all three software programs and were used in the study can be seen in Figure 6. For target gene prediction, tRF-39-0VL8K87SIRM12E2 was predicted to
discovery of these fragments, tRFs have been described in many species and organisms, as well as in cell lines including various cancer cell lines. More specifically, studies have shown that some tRFs may play a role in cancer suppression by combining with the mRNA binding protein YBX1, which is overexpressed in many cancer types and has been implicated in many key cellular pathways. In colorectal cancer for example, the combination of tRFs and miR-1280 suppresses cancer growth and metastasis by repressing Notch signaling pathways that support cancer stem cell phenotypes. Other studies have demonstrated that tRFs are expressed in patients with prostate cancer, with survival curve analyses showing that tRF expression affects both progression-free survival and prognosis.

Increasing number of studies have demonstrated the important role played by tRFs tumors. Some tRFs promote cell proliferation and cell cycle progression by regulating the expression of oncoproteins and other tRFs, thereby inhibiting cancer progression. Mechanistic studies have shown that tRFs can bind to RNA binding proteins, such as the YBX1, and prevent transcription, inactivate the initiation factor eIF4G/A, promote ribosomal protein translation, and activate aurora kinase A, a modulator of mitosis. Therefore, tRFs and tsRNAs regulate the occurrence and development of cancers of lungs, colorectum, prostate, breast, ovaries, and B cells, as well as chronic lymphocytic leukemia, among others. In breast cancer, tsRNA-19, tsRNA-29, tsRNA-46, and tsRNA-112 selectively respond to the expression of RUNX1 tumor suppressor. We found that ts-112 and RUNX1 are correlated in normal breast epithelium and breast cancer cell lines, which is consistent with the tumor-related activity of ts-112 and the tumor suppressor activity of RUNX1. The inhibitory effect of ts-112 in MCF10CA1a (an invasive breast cancer cell line) reduced proliferation significantly, while the ectopic expression of ts-112 in MCF10A (normal breast epithelial cells) increased proliferation significantly. These results verified the carcinogenic potential of ts-112. In addition, RUNX1 may inhibit ts-112 to prevent hyperproliferation of breast cancer epithelial cells, thereby confirming its role in maintaining the breast epithelium. In gastric cancer, -5034-GluTTC-2 is downregulated in gastric cancer tissue and plasma, and its level is significantly related to tumor size. The overall survival rate of patients with low -5034-GluTTC-2 expression is significantly lower than that of patients with higher expression. These results indicate that -5034-GluTTC-2 has an important relationship with the occurrence and development of gastric cancer. Studies have shown that the dysregulation of tsRNA expression is a concomitant event in the development of disease, and mature tRFs may play carcinogenic and tumor-suppressing roles in chronic lymphocytic leukemia.

In this study, we explored the composition and expression of tRFs in patients with PTC. We screened 53 tRFs and tsRNAs from thyroid cancer samples and normal tissue samples and found 19 downregulated tRFs and tsRNAs, and 34 upregulated tRFs and tsRNAs. Through qPCR verification, we confirmed that tRF-39-0VL8K87SIRMM12E2 and tRF-38-0VL8K87SIRMM12V are upregulated in PTC, whereas and tRF-34-Y5V4V7Q2WW11J1 and tRF-27-PIR8YP9LON3 are downregulated, which is consistent with our sequencing data. Repeated qPCR verification confirmed the largest expression difference of tRF-39-0VL8K87SIRMM12E2 between thyroid cancer cells and normal cells. In addition, we used the software programs MiRanda, RNAhybrid, and targetScan to predict the targets of differentially expressed tRFs and tsRNAs. Our analysis confirmed that upregulated tRF-39-0VL8K87SIRMM12E2 was mainly involved in metabolic pathways and in
cancer-related signaling pathways. Previous studies have focused on effect of tRFs on tumor occurrence and development, but little is known regarding how tRFs affect the metabolic pathways. Based on the results of our study, further research is warranted to determine how tRFs affect the occurrence and development of PTC by affecting the biological metabolism. In the near future, we plan to conduct such studies to confirm and expand the findings of the present study. This study had several limitations. The results are based only on tRF sequencing analysis and bioinformatics predictions and require validation based on in vitro and in vivo models. Additionally, the small sample size of this study led to large statistical differences between samples, necessitating the need for further studies based on large clinical cohorts.

5 | CONCLUSION

In this study, we provided a comprehensive expression profile of tRFs in PTC and identified several potential avenues of further
research, including the biological role and marker potential of tRFs in thyroid cancer.

ACKNOWLEDGMENTS
This study was supported by the Social Development Foundation of Science and Technology of Jiangsu (BE2016658), the Changzhou Sci & Tech Program (CE20165020), the High-Level Medical Talents Training Project of Changzhou (2016CZLJ007), and the Project of Changzhou medical innovation team (CCX201807).

CONFLICT OF INTEREST
The authors indicated no potential conflicts of interest.

DATA AVAILABILITY STATEMENT
All data generated or analyzed during this study are included in this published article [and its supplementary information files].

ORCID
Chunfu Zhu https://orcid.org/0000-0002-4363-5781

REFERENCES
1. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338-1348.
2. Ozden S, Comcali B, Atas H, et al. A diagnostic dilemma: skip metastasis in papillary thyroid cancer. Am Surg. 2020;86(3):245-249.
3. Huang Z, Song M, Wang S, et al. Preoperative serum thyroglobulin is a risk factor of skip metastasis in papillary thyroid carcinoma. Ann Transl Med. 2020;8(6):389.
4. Zembksa A, Jawiarczyk-Przybylowska A, Wojtczak B, Bolanowski M. MicroRNA expression in the progression and aggressiveness of papillary thyroid carcinoma. Anticancer Res. 2019;39(12):33-40.
5. Sakai T, Sugitani I, Ebina A, et al. Active surveillance for T1bNOM0 papillary thyroid carcinoma. Thyroid. 2019;29(1):59-63.
6. Rosignolo F, Memeo L, Monzani F, et al. MicroRNA-based molecular classification of papillary thyroid carcinoma. Int J Oncol. 2017;50(5):1767-1777.
7. Ma Z, Zhou J, Shao Y, et al. Biochemical properties and progress in cancers of tRNA-derived fragments. J Cell Biochem. 2020;121(3):2058-2063.
8. Su Z, Frost EL, Lammert CR, et al. tRNA-derived fragments and microRNAs in the maternal-fetal interface of a mouse maternal-immune-activation model. RNA Biol. 2020;17(8):1183-1195.
9. Kazimierczyk M, Jedroszkowiak A, Kowalczykiewicz D, et al. tRNA-derived fragments from the Sus scrofa tissues provide evidence of their conserved role in mammalian development. Biochem Biophys Res Commun. 2019;520(3):514-519.
10. Shi H, Yu M, Wu Y, et al. tRNA-derived fragments (tRFs) contribute to podocyte differentiation. Biochem Biophys Res Commun. 2020;521(1):1-8.
11. Zhong F, Hu Z, Jiang K, et al. Complement C3 activation regulates the production of tRNA-derived fragments Gly-tRFs and promotes alcohol-induced liver injury and steatosis. Cell Res. 2019;29(7):548-561.
12. Tosar JP, Cayota A. Extracellular tRNAs and tRNA-derived fragments. RNA Biol. 2020;28(8):1102-1110.
13. Green JA, Ansari MY, Ball HC, Haqqi TM. tRNA-derived fragments (tRFs) regulate post-transcriptional gene expression via AGO-dependent mechanism in IL-1beta stimulated chondrocytes. Osteoarthritis Cartilage. 2020;17(8):1149-1167.
14. Huang Y, Ge H, Zheng M, et al. Serum tRNA-derived fragments (tRFs) as potential candidates for diagnosis of nontriple negative breast cancer. J Cell Physiol. 2020;235(3):2809-2824.
15. Cosacak M, Erdogan I, Nalbant A, Akgul B. Small RNA data set that includes tRNA-derived fragments from Jurkat cells treated with camptothecin. Data Brief. 2018;17:397-400.
16. Zeng T, Hua Y, Sun C, et al. Relationship between tRNA-derived fragments and human cancers. Int J Cancer:2020;147(11):3007–3018.
17. Londin E, Magee R, Shields CL, Lally SE, Sato T, Rigoutsos I. IsomiRs and tRNA-derived fragments are associated with metastasis and patient survival in uveal melanoma. Pigment Cell Melanoma Res. 2020;33(1):52-62.
18. Martens-Uzunova ES, Jalava SE, Dits NF, et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene. 2012;31(8):978-991.
19. Goodarzi H, Liu X, Nguyen HC, Zhang S, Fish L, Tavazoie SF. Endogenous tRNA-derived fragments suppress breast cancer progression via YBX1 displacement. Cell. 2015;161(4):790-802.
20. Jin L, Zhu C, Qin X. Expression profile of tRNA-derived fragments in pancreatic cancer. OncoLett. 2019;18(3):3104-3114.
21. Adam MA, Thomas S, Roman SA, Hyslop T, Sosa JA. Rethinking the current American joint committee on cancer TNM staging system for medullary thyroid cancer. JAMA Surg. 2017;152(9):869-876.
22. Shen Y, Yu X, Zhu L, et al. Transfer RNA-derived fragments and tRNA halves: biogenesis, biological functions and their roles in diseases. J Mol Med. 2018;96(11):1167-1176.
23. Xie Y, Yao L, Yu X, et al. Action mechanisms and research methods of tRNA-derived small RNAs. Signal Transduc Target Ther. 2020;5(1):109.
24. Cui Y, Huang Y, Wu X, et al. Hypoxia-induced tRNA-derived fragments, novel regulatory factor for doxorubicin resistance in triple-negative breast cancer. J Cell Physiol. 2019;234(6):8740-8751.
25. Huang B, Yang H, Cheng X, et al. tRF/miR-1280 suppresses stem cell-like cells and metastasis in colorectal cancer. Cancer Res. 2017;77(12):3194-3206.
26. Olvedy M, Scaravilli M, Hoogstrate Y, et al. A comprehensive repertoire of tRNA-derived fragments in prostate cancer. Oncotarget. 2016;7(17):24766-24777.
27. Guzzi N, Bellodi C. Novel insights into the emerging roles of tRNA-derived fragments in mammalian development. RNA Biol. 2020;17(8):1214-1222.
28. Zhu P, Yu J, Zhou P. Role of tRNA-derived fragments in cancer: novel diagnostic and therapeutic targets tRFs in cancer. Am J Cancer Res. 2020;10(2):393-402.
29. Zhu L, Ge J, Li T, Shen Y, Guo JJC. tRNA-derived fragments and tRNA halves: the new players in cancers. Cancer Lett. 2019;452:31-37.
30. Farina N, Scala S, Adams C, et al. Identification of tRNA-derived small RNA (tsRNA) responsive to the tumor suppressor, RUNX1, in breast cancer. J Cell Physiol. 2020;235(6):5318-5327.
31. Zhu L, Li T, Shen Y, Yu X, Xiao B, Guo J. Using tRNA halves as novel biomarkers for the diagnosis of gastric cancer. Cancer Biomarkers. 2019;25(8):169-176.
32. Veneziano D, Tommasolo L, Balatti V, et al. Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia. Proc Natl Acad Sci. 2019;116(48):24252-24258.

How to cite this article: Shan S, Wang Y, Zhu C. A comprehensive expression profile of tRNA-derived fragments in papillary thyroid cancer. J Clin Lab Anal. 2021;35:e23664. https://doi.org/10.1002/jcla.23664